ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / IKT / dividends
LXEO (33) OCGN (25) PLX (28) FATE (36) ⌘ Pro Terminal β†’

Inhibikase Therapeutics Inc. (IKT) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.55 -7.19% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.53

Inhibikase Therapeutics Inc. (IKT) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (39/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE D- β€’ RED ALERT Cap $233.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IKT Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is IKT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Inhibikase Therapeutics Inc. (NASDAQ: IKT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.55 (-7.19% 1D, market cap $233.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IKT ranks #552 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does IKT compare to LXEO and OCGN in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IKT carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $251.1M) and OCGN (Ocugen Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $252.4M). Among the 5-stock peer group, IKT leads on earnings multiple (N/A) while PLX leads on capital efficiency (-13.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IKT?
β–Ό

Per IKT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001750149), Inhibikase Therapeutics Inc. generated $0 in revenue, -$48.3M in net income, and -$27.8M in free cash flow against $181.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.53 (-1.48%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (39/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510039
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D
Cash (8)Whales (10)SEC (10)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.4% Base Target
$3 Bull$1 Base$1 Bear
πŸ“¬ FREE IKT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for IKT)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (39/100 Composite)
πŸ” WHY IKT SCORES 39/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+10/20 pts (26% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
47
Grade D$1.97-16.2% Next Q
Q2 (-2Q)
44
Grade D$1.65-3.6% Next Q
Q3 (-1Q)
42
Grade D$1.59-2.5% Next Q
Current
39
Grade D-$1.55-7.6% Hist 90D Ξ±
Trajectory: D (47) β†’ D- (39)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a IKT Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While IKT currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.08) and Max Pain ($1.63) forces dealer call-delta covering toward $2.74.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IKTβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œIKT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IKT)

  • βœ“Walkthrough of IKT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
IKT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -17.99%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-10-30O $1.67H $1.67L $1.52C $1.55VOL 438.3K
RES: $2.72SUP: $1.50SMA50: $2.08SMA200: $1.94
$2.69$2.37$2.04$1.72$1.40RES $2.72SUP $1.50$1.552026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IKT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ IKT Butterfly Map β†’ + Track IKT β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IKT today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for IKT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IKT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IKT)

Health Care Rank #552 of 1016 βš”οΈ LXEO vs IKT Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (IKT vs. LXEO, OCGN, PLX, FATE)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Inhibikase Therapeutics Inc. (IKT) ranks #552 by composite RQD confidence (39/100, grade D-) and #556 by equity capitalization ($233.0M). Within this direct 5-issuer industry benchmark cohort, IKT leads on earnings valuation at N/A trailing P/E, while PLX leads on capital efficiency and profitability with -13.0% ROIC and 48.8% gross margin. IKT currently leads its immediate peer cohort in composite quantitative strength at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IKT ACTIVE
Inhibikase Therapeutics Inc.
D- 39/100 β€” β€” -35.0% -7.19% $233.0M Benchmark Subject
LXEO
Lexeo Therapeutics Inc.
E 33/100 β€” β€” -35.0% +2.61% $251.1M /lxeo-vs-ikt β†’
OCGN
Ocugen Inc.
E 25/100 β€” β€” -35.0% -5.58% $252.4M /ocgn-vs-ikt β†’
PLX
Protalix BioTherapeutics Inc.
E 28/100 β€” 48.8% -13.0% -0.77% $210.3M /plx-vs-ikt β†’
FATE
Fate Therapeutics Inc.
D- 36/100 β€” β€” -35.0% -4.15% $260.0M /fate-vs-ikt β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001750149

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inhibikase Therapeutics Inc. (IKT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$48.3M, operating cash flow of -$27.8M, and free cash flow of -$27.8M (-45.2% YoY). On the balance sheet, IKT closed FY2025 with $181.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$48.3M -$27.8M -$27.8M $181.2M β€”
FY2024 (FY) 2024-12-31 $0 -$27.5M -$19.1M -$19.1M $98.6M β€”
FY2023 (FY) 2023-12-31 $260.5K -$19.0M -$18.1M -$18.1M β€” β€”

3. IKT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IKT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Inhibikase Therapeutics Inc. (NASDAQ: IKT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.55 (-7.19% 1D, market cap $233.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IKT ranks #552 in composite RQD confidence.

How does IKT compare to LXEO and OCGN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IKT carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $251.1M) and OCGN (Ocugen Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $252.4M). Among the 5-stock peer group, IKT leads on earnings multiple (N/A) while PLX leads on capital efficiency (-13.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IKT?

Per IKT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001750149), Inhibikase Therapeutics Inc. generated $0 in revenue, -$48.3M in net income, and -$27.8M in free cash flow against $181.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IKT trading relative to its 50-day, 200-day, and 52-week technical levels?

IKT last traded at $1.55 (-7.19% on volume of 438,290 shares), positioning the stock -25.48% below its 50-day simple moving average ($2.08) and -20.10% below its 200-day simple moving average ($1.94). Across its 52-week range of $1.33 to $2.61, IKT sits at the 17.2% percentile with a 14-day RSI of 33.6 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.36 to $1.74).

IKT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Does IKT pay a dividend and is it safe?

Inhibikase Therapeutics Inc. (IKT) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: IKT RQD Cockpit IKT 12M Forecast IKT Earnings & Move IKT Dividends & DRIP IKT Insiders & 13F IKT Whale Options IKT Profit Sankey IKT News & Why
ROARABLE RATING BRIEF β€’ RQD 39/100 (D-) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

IKT β€” Inhibikase Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:40:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IKT scores 39 out of 100 with a letter grade of D-, labeled "Roarable Sell β€” Vulnerable Balance Sheet & Flow." The five pillars are:

  • Fundamental Cash Engine: 8 / 20. Return on invested capital is -35% and FCF yield is -11.93%. For a prospective investor, this means the business is not currently generating cash from operations; value depends on future development outcomes rather than current earnings power.
  • Whale / 13F Flow: 10 / 20. The rating references institutional accumulation and options positioning, but the holders section contains no detail, so the specific direction and size of institutional activity cannot be confirmed from the source data.
  • Insider Conviction: 3 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow at a low score. No individual insider transactions are itemized in the source data.
  • Macro Regime Fit: 8 / 20. Beta is 1.0, and the rating notes sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broad market; the sector sensitivity component is not further itemized.
  • Forensic Balance Sheet: 10 / 20. Per the same rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These readings point to a balance sheet that is not clearly strong on the Piotroski test, though the Altman figure sits in a range the rating treats as moderately sound.

Taken together, the score reflects weak current cash generation, low insider conviction, and a balance sheet that scores only middling on forensic checks. A prospective investor should weigh whether the stock's valuation and pipeline outcomes, which the source data does not detail, justify holding exposure to these risks.

Business

Inhibikase Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company has a market capitalization of $0.2B. The source data does not describe its products, customers, or specific revenue model. Reported revenue is $0.0M in FY 2025 and FY 2024, with $0.3M in FY 2023.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-52.0M$-48.3MN/A$-27.8M$178.8MN/A
FY 2024$0.0M$-28.6M$-27.5MN/A$-19.1M$97.5MN/A
FY 2023$0.3M$-20.1M$-19.0MN/A$-18.1MN/AN/A

Per the SEC financials, the company reported operating losses in each period shown, widening from $-20.1M in FY 2023 to $-52.0M in FY 2025. Gross, operating, and net margins are each recorded as 0% in the market data, and ROIC is -35%. The per-the-Roarable-RQD-rating Altman Z-Score of 2.5 and Piotroski F-Score of 2/9 are the only forensic balance-sheet readings provided. Cash rose to $178.8M at FY 2025 from $97.5M at FY 2024, while debt is not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the most recent item is a board appointment, with Scott Wasserman joining the Board of Directors. Coverage also includes a MarketBeat report citing a consensus target price of $4.75 and a Chardan initiation with a neutral rating (reported via Investing.com Canada). A GlobeNewswire release announces participation in upcoming investor conferences during November 2026. All news items are tagged with a YELLOW signal light and "MARKET WIRE" impact label. The Butterfly Supply-Chain Graph contains no supply-chain links or proprietary signals.

Analyst View & Smart Money Ownership

Analyst data is not available in source data. Holder data is not available in source data. The news feed references a consensus target price of $4.75 and a neutral initiation, but these figures are not verified against the analyst data section.

Open Questions

  • What are the company's products, development programs, and revenue model, given that reported revenue is $0.0M in the most recent two fiscal years?
  • What is the company's debt position, since the debt field is N/A for every reported period?
  • What drove the rise in cash from $97.5M to $178.8M between FY 2024 and FY 2025, and what is the current runway at the FY 2025 FCF burn rate?
  • What institutional and insider holdings exist, given the holders section is empty?
  • What does the consensus analyst view consist of, given the analyst data section is empty?

IKT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Inhibikase Therapeutics Inc. (IKT) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to IKT Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IKT Bull vs. Bear Conversation Board β€” What's Your Call at $1.55?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IKT 🐻 67% BEARISH CONVICTION
1. Pick Your Side on IKT:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.36 (-12.3%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is IKT (D- β€’ RQD 39/100) a Buy at $1.55?

Welcome to the IKT (Inhibikase Therapeutics Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell β€” Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.19 (-23.2%)
Spot @ $1.55

Pump the brakes on IKT β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IKT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Inhibikase Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $1.88 (+21.3%)
Spot @ $1.55

IKT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IKT, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.55 (52-wk range $1.33 - $2.61), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%